Tirzepatide once weekly for the treatment of adults with overweight or obesity
Phase 3, randomized, double-blind, placebo-controlled dose-ranging trial (SURMOUNT-1).
Who or what was studied.
Main findings.
Over 72 weeks, participants randomized to tirzepatide 15 mg once weekly had a mean body-weight change of −20.9%, versus −3.1% with placebo. The 5 mg and 10 mg doses produced mean changes of −15.0% and −19.5%, respectively. All tirzepatide dose groups met the prespecified primary and key secondary weight-loss objectives.
Limitations.
Key limitations: the 72-week treatment window does not establish long-term safety or durability of effect; exclusion criteria limit generalizability to broader or more medically complex populations; and the trial compared tirzepatide with placebo rather than with other active treatments. Gastrointestinal adverse events were the most common reason for discontinuing tirzepatide.
Compounds & topics.
For plain-language guides on these compounds, see the peptide hub and the peptide encyclopedia.